Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Baxter
Harvard Business School
Chubb
UBS

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,214,865

« Back to Dashboard

Which drugs does patent 6,214,865 protect, and when does it expire?

Patent 6,214,865 protects HALAVEN and is included in one NDA.

This patent has forty patent family members in twenty-one countries.

Summary for Patent: 6,214,865
Title: Macrocyclic analogs and methods of their use and preparation
Abstract:The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Palme; Monica H. (San Jose, CA), Seletsky; Boris M. (Andover, MA), Towle; Murray J. (Auburn, NH), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonberry, NH)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:09/334,488
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,214,865
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 6,214,865

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Colorcon
Argus Health
Boehringer Ingelheim
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.